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Abstract
We examined the impact of statins on Yes-associated Protein (YAP) localization, phosphor-
ylation and transcriptional activity in human and mouse pancreatic ductal adenocarcinoma
(PDAC) cells. Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin
or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm
and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth
Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Statins also prevented
YAP nuclear import and expression of CTGF and CYR61 stimulated by the mitogenic
combination of insulin and neurotensin in dense culture of these PDAC cells. Cerivastatin,
simvastatin, atorvastatin and fluvastatin also inhibited colony formation by PANC-1 and Mia-
PaCa-2 cells in a dose-dependent manner. In contrast, the hydrophilic statin pravastatin did
not exert any inhibitory effect even at a high concentration (10 μM). Mechanistically, cerivas-
tatin did not alter the phosphorylation of YAP at Ser127 in either PANC-1 or MiaPaCa-2 cells
incubated without or with neurotensin and insulin but blunted the assembly of actin stress
fiber in these cells. We extended these findings with human PDAC cells using primary KC
and KPC cells, (expressing KrasG12D or both KrasG12D and mutant p53, respectively) iso-
lated from KC or KPC mice. Using cultures of these murine cells, we show that lipophilic stat-
ins induced striking YAP translocation from the nucleus to the cytoplasm, inhibited the
expression of Ctgf, Cyr61 and Birc5 and profoundly inhibited colony formation of these cells.
Administration of simvastatin to KC mice subjected to diet-induced obesity prevented early
pancreatic acini depletion and PanIN formation. Collectively, our results show that lipophilic
statins restrain YAP activity and proliferation in pancreatic cancer cell models in vitro and
attenuates early lesions leading to PDAC in vivo.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is
one of the most fatal human diseases, with an overall 5-year survival rate of only 7%. It has
been anticipated that PDAC will be the 3rd leading cause of cancer-related mortalities in the
USA by the end of 2018 [1] and projected to become the 2nd leading cause of cancer-related
mortality in the USA before 2030 [2]. Consequently, new approaches for the treatment and
prevention of PDAC are urgently needed.
PDAC arises from precursor lesions, the most common of which are pancreatic intraepithe-
lial neoplasia (PanIN) [3, 4]. Virtually all PanIN lesions and invasive PDAC entail activating
mutations in the KRAS oncogene, which represent an initiating event in the development of
the disease [5, 6]. In line with this concept, the model that best recapitulates the progression of
human PDAC in mice involves expression of a mutant Kras (KrasG12D) from the endogenous
Kras locus [7]. Administration of an obesogenic diet markedly accelerates PanIN formation
and PDAC development in this model [8, 9]. The identification of novel targets and agents for
prevention and interception [10] requires a detailed understanding of the signaling mecha-
nisms and gene regulatory programs that stimulate the proliferation of PDAC cells [7].
Recent evidence indicates that the transcriptional co-activators Yes-Associated Protein
(YAP) and WW-domain-containing Transcriptional co-Activator with PDZ-binding motif
(TAZ), two central effectors of the highly conserved Hippo pathway [11–13], act as potent
oncogenes in PDAC [14–17] and in the control of differentiation of pancreatic cells to differ-
ent lineages [18]. The Hippo pathway consists of a serine/threonine kinase cascade in which
Mst1/2 kinases phosphorylate and activate Lats1/2, which phosphorylate YAP and TAZ at spe-
cific residues that regulate their localization and protein stability [11, 12]. In its unphosphory-
lated state, YAP localizes to the nucleus where it binds and activates predominantly the TEA-
domain DNA-binding transcription factors (TEAD 1–4) thereby stimulating the expression of
multiple genes, including Connective Tissue Growth Factor (CTGF) and Cysteine-rich angio-
genic inducer 61 (Cyr61). Independently of the Hippo pathway, YAP/TAZ localization and
activity is highly responsive to the organization of the actin filament [13]. Consequently, YAP/
TAZ activity represents a key point of convergence in the signaling by Ras, Rho, tyrosine
kinase receptors, G protein-coupled receptors (GPCR), integrins, mechanical cues and cell
density, all of which regulate the organization of the actin cytoskeleton and play a critical role
in PDAC development [13, 19–23]. Several studies indicate that YAP/TAZ is up-regulated in
PDAC tumor samples [24–26] and higher expression of YAP is correlated with poorer survival
in PDAC patients [17, 27]. Furthermore, amplification and overexpression of Yap can substi-
tute for mutant Kras expression in preclinical models of PDAC [24]. In view of all these find-
ings, there is intense interest in targeting YAP/TAZ to prevent or intercept PDAC
development.
Although inhibition of the activity of transcription factors or their co-activators has proven
a difficult strategy, recent evidence suggests a new avenue to target YAP/TAZ activity via the
use of statins in PDAC and other malignancies. Many studies showed that the mevalonate
pathway is markedly upregulated in several epithelial cancers, including PDAC [28–31]. Statins
are specific inhibitors of the 3-hydroxy-methylglutaryl (HMG) CoA reductase [32, 33], the rate-
limiting enzyme in the generation of mevalonate, the first step in the biosynthesis of isopren-
oids, leading to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and
cholesterol [34]. The transfer of the geranylgeranyl moiety of GG-PP to a COOH-terminal cys-
teine of Rho GTPases is critical for their membrane localization and function in signal transduc-
tion through actin remodeling [12]. Accordingly, YAP and TAZ act as novel sensors of
mevalonate metabolism and statins as inhibitors of their nuclear localization and transcriptional
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activity, at least in some cell types [35–37]. Statins, which are usually well tolerated and generally
safe, have long been used to treat hypercholesterolemia and prevent cardiovascular diseases.
Recent epidemiological studies imply that use of statins is associated with beneficial effects in
PDAC [38–47], and other malignancies [48]. In a previous preclinical study, statin administra-
tion delayed PDAC in mice harboring KrasG12D but the incidence of PDAC in this report was
unusually high and the connection between statin and YAP activity was not examined [49]. Fur-
thermore, the impact of statins on the initial stages of PDAC, namely depletion of pancreatic
acini (acinar-ductal metaplasia) and formation of PanIN lesions induced by an obesogenic diet
in conditional KrasG12D (KC) mice remains unknown.
In the present study, we determined the impact of different statins on YAP localization, and
transcriptional activity in human and murine PDAC cells. In order to determine whether stat-
ins act via stimulation of the Hippo pathway, we also examined the influence of statins on YAP
phosphorylation at Ser127, a residue targeted by LATS1/2. Subsequently, we assessed the
impact of simvastatin administration on pancreatic acini depletion and PanIN formation
using KC mice subjected to diet-induced obesity (DIO), which accelerates PanIN formation
and PDAC development [8, 9, 50]. Our results show that exposure of PDAC cells to lipophilic
statins, including cerivastatin and simvastatin, inhibits YAP nuclear localization, transcrip-
tional activity and colony formation via a phosphorylation-independent mechanism. Adminis-
tration of simvastatin to KC mice subjected to DIO attenuated early pancreatic acini depletion
and PanIN formation. Collectively, our results provide preclinical evidence that statins restrain
YAP activity and proliferation in pancreatic cancer cell models in vitro and attenuates early
lesions leading to PDAC in vivo
Material and methods
Cell culture
The human pancreatic cancer cell lines PANC-1 and MiaPaCa-2 were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). These cell lines were chosen
because they harbor mutations typical of human pancreatic cancer, including mutations in
KRAS and TP53 (encoding the p53 protein) and deletion of CDKN2A (also known as p16 or
p16INK4a). These cell lines, authenticated by ATCC by short-tandem repeat analysis, were used
within 15 passages and cultured for less than 6 months after recovery from frozen stocks (no
authentication was done by the authors). PANC-1 and Mia PaCa-2 cells were grown in Dul-
becco’s modified Eagle Medium (DMEM) with 2 mM glutamine, 1 mM Na-pyruvate, 100
units/mL penicillin, and 100 μg/mL streptomycin and 10% fetal bovine serum (FBS) at 37˚C in
a humidified atmosphere containing 10% CO2.
Primary KC and KPC cells, (expressing KrasG12D or both KrasG12D and mutant p53,
respectively) isolated from KC or KPC mice, were a kind gift from Dr. Ashok Saluja, (Professor
and Vice-Chair, Department of Surgery, Director, Sylvester Pancreatic Cancer Research Insti-
tute, University of Miami). KC and KPC cells were validated by PCR analysis of genomic
DNA. These cells were cultured in RPMI 1640 medium with 2 mM glutamine, 100 units/mL
penicillin, and 100 μg/mL streptomycin and 5% fetal bovine serum (FBS) at 37˚C in a humidi-
fied atmosphere containing 5% CO2.
Experimental animals
After weaning, offspring of LSL-KrasG12D/+ and p48-Cre+/− mice were randomly allocated
to a control diet (CD), a high fat, high calorie diet (HFCD), or a HFCD plus simvastatin
(40mg/kg). All mice had free access to the diet, body weights were measured weekly and the
general health and behavior of animals were assessed daily. After 14 weeks, mice were
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euthanized and the entire pancreas was harvested for histological analysis. All studies involving
animals were reviewed and approved by the Chancellor’s Animal Research Committee of the
University of California, Los Angeles in accordance with the NIH Guide for the Care and Use
of Laboratory Animals (protocol number: 2011–118)
Genotyping analysis
LSL-KRASG12D and Cre alleles were detected prior to randomizing to the experimental diets
by PCR analysis of genomic DNA, as described [51]. Mutant (KC) mice expressed both
LSL-KRASG12D and Cre alleles, and animals carrying neither allele were labeled wild type
(WT).
Experimental diets
Diets were prepared by Dyets, Inc. (Bethlehem, PA). At one month of age, mice were random-
ized to receive either the CD, HFCD, or HFCD with simvastatin (40mg/kg) from Sigma-
Aldrich, (St. Louis, MO) in the food. A detailed composition of the diets was described previ-
ously [9]. Briefly, while the CD contained 12% calories from fat, 40% of calories in the HFCD
stem from fat (corn oil-based). All diets were stored at −20˚C (long-term) or 4˚C (short-term)
in sealed containers and prepared under low light conditions. The diets were replaced on a
weekly basis.
Pancreas and liver histology
Hematoxylin and eosin (H&E) stained tissue sections of the pancreas, fixed in formalin and
embedded in paraffin, were assessed by gastrointestinal pathologists blinded to the experimen-
tal groups. The presence and stage of murine PanINs were analyzed as described previously
[9]. For each animal approximately 100 pancreatic ducts (tail of the pancreas) were quantified
and the proportion of murine PanIN-3 to the overall number of pancreatic ducts was
recorded.
Western blot analysis
Confluent cultures of PANC-1 or MiaPaCa-2 cells, grown on 35 mm tissue culture dishes,
were washed twice with DMEM and incubated in serum-free medium for 4 h and then treated
as described in individual experiments. The cultures were then directly lysed in 2 × SDS-PAGE
sample buffer [200 mM Tris-HCl (pH 6.8), 2 mM EDTA, 0.1 M Na3VO4, 6% SDS, 10% glyc-
erol, and 4% 2-mercaptoethanol], followed by SDS-PAGE on 4–15% gels and transfer to
Immobilon-P membranes (Millipore, Billerica, MA). For detection of proteins, membranes
were blocked using 5% nonfat dried milk in PBS, pH 7.2, and then incubated overnight with
the desired antibodies diluted in PBS containing 0.1% Tween. Primary antibodies bound to
immunoreactive bands were visualized by enhanced chemiluminescence (ECL) detection with
horseradish peroxidase-conjugated anti-mouse, anti-rabbit antibody and a FUJI LAS-4000
mini luminescent image analyzer. Quantification of non saturated bands was performed using
the FUJI Multi Gauge V3.0 analysis program.
Immunofluorescence
Immunofluorescence of PANC-1 and MiaPaCa-2 cells was performed by fixing the cultures
with 4% paraformaldehyde followed by permeabilization with 0.4% Triton X-100. After exten-
sive PBS washing, fixed cells were incubated for 2h at 25˚C in blocking buffer (BB), consisting
of PBS supplemented with 5% bovine serum albumin and then stained at 4˚C overnight with a
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YAP mouse mAb (1:200) diluted in BB. Subsequently, the cells were washed with PBS at 25˚C
and stained at 25˚C for 60 min with Alexafluor 488—conjugated goat-anti mouse diluted in
BB (1:100) and washed again with PBS. Nuclei were stained using a Hoechst 33342 stain
(1:10,000). For staining of F-actin, fixed cells were blocked with 5% bovine serum albumin in
PBS. The cells were then incubated with TRITC-conjugated phalloidin (0.25 μg/ml) in PBS for
10 min at room temperature and washed five times with PBS. Images were captured as uncom-
pressed 24-bit TIFF files captured with an epifluorescence Zeiss Axioskop and a Zeiss (Achro-
plan 40/.75W objective) and a cooled (−12˚C) single CCD color digital camera (Pursuit,
Diagnostic Instruments) driven by SPOT version 4.7 software. AlexaFluor 488 signals were
observed with a HI Q filter set 41001 and TRITC images with a HI Q filter set 41002c (Chroma
Technology).
Image analysis
For YAP localization the average fluorescence intensity in the nucleus and just outside the
nucleus (cytoplasm) was measured to determine the nuclear/cytoplasmic ratios. All Image
analysis was performed using Zeiss analysis imaging software. The selected cells displayed in
the appropriate figures were representative of 80% of the population.
Quantitative reverse transcription PCR (qRT-PCR)
Relative transcript expression levels of CTGF and CYR61 were determined by qRT-PCR using
a TaqMan Gene Expression Assay. Briefly, total RNA was extracted from cells by using a Pure-
Link RNA Mini Kit. Reverse transcription was performed with the High-Capacity cDNA
Reverse Transcription Kit using 1μg of total input RNA. The synthesized cDNA samples were
used as templates for the real-time (RT) PCR analysis. All reactions were performed using the
Applied Biosystems StepOne system and the amplifications were done using the TaqMan Fast
Advanced Master Mix. The following primers were used; gene-specific Homo sapiens oligonu-
cleotides for CTGF (Assay ID: Hs01026927_g1), CYR61 (Assay ID: Hs99999901_s1) and gene-
specific Mouse oligonucleotide primers for Ctgf (Assay ID: Mn00438890_m1), Cyr61 (Assay
ID: Mm00487498_m1), Birc5 (Mn00599749_m1) the internal control was 18s (Assay ID:
Hs99999901_s1) all were from Life Technologies, Carlsbad, CA.
Colony formation
For cell colony formation, 500 PANC-1, MiaPaCa-2, KC or KPC cells were plated into 60-mm
tissue culture dishes either in DMEM containing 10% FBS or RPMI 1640 containing 5% FBS.
After 24 h of incubation at 37˚C, cultures were transferred to DMEM containing 3% FBS
(PANC-1, MiaPaCa-2) or RPMI 1640 containing 1% FBS (KC, KPC) either in the absence or
presence of statins, as indicated in the individual experiments. A colony consisted of at least 50
cells. Cell colony numbers from at least three dishes per condition were determined after 6 to
10 days of incubation.
Transfection of GFP-AKT-PH
PANC-1 cells were transfected with the plasmid containing a cDNA encoding a green fluores-
cent protein (GFP) tagged-AKT pleckstrin homology domain (pcDNA3-AKT-PH-GFP was a
gift from Craig Montell, Addgene plasmid # 18836) by using Lipofectamine 3000 as suggested
by the manufacturer. Analysis of the cells were performed 24 h after transfection.
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Measurement of intracellular concentration of Ca2+ ([Ca2+]i)
PANC-1 ells grown on glass coverslips for 4–5 d were washed in Hanks’ balanced salt solution
supplemented with 0.03% NaHCO3, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.4 mM MgSO4, and
0.1% BSA (pH 7.4) (Hanks’ buffer). Cells were then incubated with 5 μm fura 2-tetra-acetoxy
methyl ester (fura 2-AME) for 10 min in a 37 C incubator. Coverslips were then washed with
Hanks’ buffer and then and mounted in a standard 1-cm path length cuvette containing
Hanks’ buffer, and the cuvette was placed into a Hitachi (Tokyo, Japan) F-2000 fluorospectro-
photometer. The incubation medium in the cuvette was continuously stirred at 37 C. The size
of the detection window allowed measurement on the order of 105 cells. Excitation was set to
340 and 380 nm, and emission signal was collected at 510 nm, all with a 10-nm bandwidth.
Samples were taken every 0.5 s using associated software (F-2000 Intracellular Cation Mea-
surement System; Hitachi Instruments). The software created the 340/380 nm ratios, which
are proportional to [Ca2+]i.
Materials
DMEM, FBS, goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 488, Fura-2
AM and all RT-qPCR reagents were obtained from Invitrogen (Carlsbad, CA). Neurotensin,
insulin and phalloidin-TRITC were obtained from Sigma Chemical (St. Louis, MO). The gera-
nylgeranyl transferase I (GGTase I) inhibitor GGTI 298, PI 3-Kinase inhibitor A66 and the
MEK inhibitor PD0325901 were from R&D Systems (Minneapolis, MN). The dual PI3K/
mTOR inhibitor NPV-BEZ235 was purchasedfrom Selleck Chemicals (Houston, TX). Primary
antibodies used were as follows: YAP (H-9, sc-271134 and 63.1, sc-101199, final dilution 1:200
for immunofluorescence), tubulin (sc-5274; final dilution 1:400), actin (sc-47778; final dilution
1:400) and GAPDH (sc-365062; final dilution 1:400) (Santa Cruz Biotechnology); phospho-
YAP Ser127 (D9W2I, 13008; final dilution 1:1000), YAP (15028; final dilution 1:1000 for west-
ern blots), phospho-p70 S6 KinaseThr389) (9205; final dilution 1:1000) and phospho-S6 Ribo-
somal Protein Ser240/244 (5364; final dilution 1:1000), phospho LATS Thr1079 (8654; final
dilution 1:1000) and LATS2 (5888; final dilution 1:1000) were from Cell Signaling Technology
(Danvers, MA). Horseradish peroxidase–conjugated anti-rabbit IgG and anti-mouse IgG were
from GE Healthcare Bio-Sciences Corp (Piscataway, NJ). All other reagents were of the highest
grade available.
Results
Statins inhibit YAP nuclear localization and activity in sparse cultures of
PDAC cells
Initially, we examined whether YAP localization depends on cell density in human PDAC
cells. Specifically, PANC-1 and MiaPaCa-2 cells, plated at low densities, were fixed after 1, 3 or
7 days of culture. YAP was visualized by immunofluorescent staining. At lower cell densities (1
or 3 days in culture), YAP was localized prominently in the nucleus of PANC-1 and MiaPaCa-
2 cells (Fig 1A, Left). In contrast, YAP was primarily in the cytoplasm of PANC-1 and Mia-
PaCa-2 cells maintained in culture for 7 days. The quantification of YAP nuclear/cytoplasmic
ratio in multiple cells corroborated this conclusion (Fig 1A, Bars).
Next, we examined whether inhibition of mevalonate synthesis by statins regulates the
localization of YAP in PDAC cells. Cultures of PANC-1 or MiaPaCa-2 cells were plated at low
density, grown for 24 h and treated without or with cerivastatin at 0.3 μM for an additional 24
h. Then, the cultures were fixed and YAP localization was determined. As shown in Fig 1B,
exposure to cerivastatin induced a striking re-localization of YAP from the nucleus to the
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cytoplasm, as verified by quantification of YAP nuclear/cytoplasmic ratio by image analysis
(Fig 1B, Bars). Exogenously added mevalonic acid prevented the nuclear extrusion of YAP
induced by exposure to cerivastatin in either PANC-1 or MiaPaCa-2 cells (Fig 1B). The results
imply that statins induce YAP cytoplasmic localization in PDAC cells through inhibition of
3-hydroxy-methylglutaryl CoA reductase, the rate-limiting enzyme in mevalonic acid
synthesis.
In line with the cytoplasmic localization induced by exposure to cerivastatin, treatment of
PANC-1 or MiaPaCa-2 cells with this statin markedly reduced the mRNA levels of the YAP/
TEAD-regulated gene CTGF (Fig 1C). CTGF is one of the best-characterized direct target gene
of YAP that contains three putative YAP-TEAD binding sites (GGAATG) in its promoter
region. In addition, simvastatin also inhibited CTGF expression in PANC-1 and MiaPaCa-2
(Fig 1C). Exposure to cerivastatin or simvastatin also inhibited the expression of Cyr61,
another YAP/TEAD-regulated gene (Fig 1D). These results indicate that lipophilic statins reg-
ulate YAP localization and co-activator transcriptional activity in PANC-1 and MiaPaCa-2
cells.
Statins inhibit the stimulation of YAP activity induced by neurotensin and
insulin in dense cultures of PDAC cells
In previous studies, we identified potent positive crosstalk between insulin/IGF-1 receptors
and G protein-coupled (GPCR) signaling systems in PDAC cells leading to early signaling and
subsequent proliferation [52–57]. Recently, we reported that stimulation of dense cultures of
PANC-1 or MiaPaCa-2 cells with a combination of insulin and the GPCR agonist neurotensin
promoted YAP nuclear localization and stimulated the expression of YAP/TEAD-regulated
genes [58]. Here, we determined whether prior exposure to statins prevents YAP nuclear local-
ization and transcriptional activity in confluent cultures of PDAC cells challenged with these
growth-promoting agonists. PDAC cells maintained in culture for 5 days were transferred to
medium containing low serum and treated with or without cerivastatin at 0.3 μM for 24 h and
then stimulated with a combination of 10 ng/ml insulin and 5 nM neurotensin. In line with
recent results [58], stimulation of PDAC cells with insulin and neurotensin induced robust
translocation of YAP to the nucleus in either PANC-1 (Fig 2A) or MiaPaCa-2 cells (Fig 2B).
Prior exposure of these cells to 0.3 μM cerivastatin prevented YAP translocation to the nucleus
induced by insulin and neurotensin (Fig 2), as verified by quantification of YAP nuclear/cyto-
plasmic ratio by image analysis (Fig 2, Bars).
Nuclear extrusion of YAP induced by statin is expected to reduce the transcriptional activ-
ity of TEAD. Consequently, we determined the effect of statins on YAP/TEAD-regulated gene
expression induced by crosstalk between insulin and neurotensin. As shown in Fig 3, stimula-
tion of confluent PANC-1 or MiaPaCa-2 cells with neurotensin and insulin induced a marked
increase in the level of CTGF and CYR61 transcripts, as determined by RT-qPCR. Treatment
with cerivastatin completely blocked the increase in the expression of these genes at a
Fig 1. Statins induce re-distribution of YAP to the cytoplasm and inhibit YAP/TEAD-regulated genes in PDAC cells. A, PANC-1 and Mia
PaCa-2 cells were fixed with 4% paraformaldehyde 1, 3 and 7 days after plating, as indicated. B, PANC-1 and Mia PaCa-2 cells were incubated in
either absence or presence of 0.3 μM cerivastatin (Cer) added 1 day after plating and for 24 h. either with or without 250 μM mevalonic acid Then,
the cells were fixed with 4% paraformaldehyde. In A and B the cultures were stained with an antibody that detects total YAP. Bars represent the
ratio of nuclear/cytoplasm (50 to 75 cells) mean ± S.E. with similar results obtained in three independent experiments (T-test p values comparing
the indicated groups to control were ��p<0.01). C and D, PANC-1 and MiaPaCa-2 cells were incubated in either absence or presence of
cerivastatin (Cer) at 0.1 and 1 μM or simvastatin (sim) at 0.3 and 3 μM, as indicated. Statins were added 1 day after plating and the incubation
continued for 24 h. RNA was then isolated and the relative levels (n = 3) of CTGF (C) or CYR61 (D) mRNA compared with 18s mRNA was
measured by RT-qPCR. Data are presented as mean ± SEM of 5 independent experiments for CTGF and 3 independent experiments for CYR61.
Cerivastatin and simvastatin groups vs control �p<0.05, ��p<0.01.
https://doi.org/10.1371/journal.pone.0216603.g001
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concentration as low as 0.1 μM. Similarly, treatment with simvastatin (3 μM) prevented the
increase in the mRNA levels of CTGF and CYR61 induced by insulin and neurotensin. Thus,
treatment with lipophilic statins induced YAP cytoplasmic localization and inhibited YAP/
TEAD-regulated gene expression either in rapidly growing sparse cultures of PDAC cells (Fig
1) or in dense cultures of these cells re-stimulated via crosstalk between the GPCR agonist neu-
rotensin and insulin (Figs 2 and 3).
Statins inhibit colony formation by PDAC cells
Having established that statins promote cytoplasmic localization and inhibit YAP/TEAD-reg-
ulated gene expression in PDAC cells, we next determined whether statins also inhibit the
Fig 2. Cerivastatin inhibits YAP nuclear localization induced by stimulation with neurotensin and insulin in confluent PDAC cells. Confluent cultures
of PANC-1 (A) or Mia PaCa-2 (B) cells were incubated either in the absence or presence of 0.3μM cerivastatin (Cer) for 24 h. The cultures were then
stimulated without (-) or with a combination of 5 nM neurotensin and 10 ng/ml insulin (NT+Ins) for 60 min. The cultures were then washed, fixed with 4%
paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. Bars represent the ratio of
nuclear/cytoplasm (100 to 125 cells). Cerivastatin significantly decreased NT+Ins nuclear localization of YAP as compared with untreated controls
(��P< 0.01) as shown by t-test.
https://doi.org/10.1371/journal.pone.0216603.g002
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proliferation of PANC-1 and MiaPaCa-2 cells by assessing the inhibitory effects of these drugs
on the colony-forming ability of these PDAC cells. To this end, we plated single cell suspen-
sions of PANC-1 or MiaPaCa-2 cells onto 60 mm dishes (500 cells per dish) in the absence or
presence of increasing concentrations of different statins and determined the number of colo-
nies formed after 8–10 days of incubation.
Addition of cerivastatin to the medium potently inhibited colony formation by PANC-1 or
MiaPaCa-2 cells in a dose-dependent manner (Fig 4). Half-maximal inhibitory effect (IC50)
Fig 3. Exposure to lipophilic statins inhibits the expression of CTGF and CYR61 induced by stimulation with neurotensin and insulin in PDAC cells.
Confluent cultures of PANC-1 cells (upper panel) or MiaPaca-2 cells (lower panel) were incubated for 24 h either without or with cerivastatin (Cer) at 0.1
and 0.3 μM or simvastatin (sim) at 3 and 10 μM, as indicated. The cultures were then stimulated either without (-) or with a combination of 5 nM
neurotensin and 10 ng/ml insulin (NT+Ins) for 60 min. RNA was isolated and the relative levels (n = 3) of CTGF or CYR61 mRNA compared with 18s
mRNA was measured by RT-qPCR. Data are presented as mean ± SEM. Similar results were obtained in 3 independent experiments. Exposure to
cerivastatin and simvastatin significantly decreased relative mRNA levels of CTGF and CYR61 as compared with controls (��P< 0.01) as shown by paired
t-test.
https://doi.org/10.1371/journal.pone.0216603.g003
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was achieved at a concentration of cerivastatin as low as 0.03 μM. Maximal inhibition of col-
ony formation was obtained at 0.3 μM. Addition of mevalonic acid (250 μM) reversed
completely (PANC-1) or partially (MiaPaCa-2) the inhibitory effect of low concentrations
(0.1–0.3 μM cerivastatin) on colony formation. These results are consistent with the notion
that the statins, at low concentrations, block colony formation by PDAC cells through inhibi-
tion of 3-hydroxy-methylglutaryl CoA reductase, the rate-limiting enzyme in the generation of
mevalonic acid, and with our previous results showing that knockdown of YAP/TAZ prevents
colony formation by either PANC-1 or MiaPaCa-2 cells [58].
We also determined whether other lipophilic statins inhibit colony formation by PDAC
cells. As shown in Fig 4, simvastatin inhibited colony formation by PANC-1 and MiaPaCa-2
cells in a dose-dependent manner with half-maximal effect achieved at 0.3 μM. In addition,
atorvastatin and fluvastatin also reduced colony formation by PANC-1 cells in a dose-depen-
dent manner. In sharp contrast, the hydrophilic statin pravastatin did not exert any inhibitory
effect even at a concentration as high as 10 μM. This is likely due to the low uptake of prava-
statin in pancreatic cancer cells [59]. These results indicate that cell-permeable lipophilic stat-
ins, including cerivastatin, simvastatin, atorvastatin and fluvastatin potently inhibit colony
formation by PDAC cells.
Mechanism by which statins induce cytoplasmic localization and inhibit
transcriptional activity of YAP: role of YAP phosphorylation and actin
organization
It is widely recognized that statins deplete several important lipid intermediates, including ger-
anylgeranyl pyrophosphate (GGPP), a critical isoprenoid in Rho prenylation. A key enzyme in
this process is geranylgeranyl transferase (GGTase) that catalyzes the transfer of GG to Rho. In
line with this notion, the selective inhibitor of GGTase, GGTI 298, mimicked the inhibitory
effect of statins on colony formation by PDAC cells (Fig 5A).
The precise mechanism linking Rho to YAP activity in PDAC cells remains incompletely
understood. In other cell types, statin treatment appears to increase YAP phosphorylation at
Ser127 through a Hippo-independent but Rho-inhibited kinase pathway [35, 37]. So far, the
putative Rho-sensitive kinase remains unidentified. In contrast, we found that exposure to cer-
ivastatin did not alter the phosphorylation of YAP at Ser127 in either PANC-1 (Fig 5B) or Mia-
PaCa-2 (Fig 5C) cells incubated either without or with neurotensin and insulin. These results
were reproduced in 9 separate experiments. In addition, we did not detect any consistent
increase in the phosphorylation of YAP at Ser127 or change in total YAP in PANC-1 (Fig 5D)
or MiaPaCa-2 (Fig 5E) cells treated with different concentrations of cerivastatin or simvastatin
without or with stimulation by insulin and neurotensin. Accordingly, we did not detect any
change in LATS phosphorylation at Thr1079 or in total LATS in response to these treatments in
PANC-1 (Fig 5D) or MiaPaCa-2 (Fig 5E) cells These results indicate that statins inhibit YAP
nuclear localization and co-activator activity independently of its phosphorylation at Ser127 in
PDAC cells.
Fig 4. Lipophilic statins inhibit colony-formation by PDAC cells. Colony formation assays were performed as
described in the Materials and Methods section. PANC-1 or MiaPaCa-2 cells were incubated for 10 days (PANC-1
cells) or 8 days (Mia PaCa-2 cells) with various concentrations of lipophilic statins, such as cerivastatin, simvastatin,
atorvastatin, fluvastatin or the hydrophilic statin pravastatin, as indicated. Typical pictures are shown for selected
conditions The bars represent the number of colonies (mean ± SEM; n = 4 dishes per condition). Similar results were
obtained in 6 independent experiments for cerivastatin, 4 for simvastatin and 3 for atorvastatin, fluvastatin and
pravastatin.
https://doi.org/10.1371/journal.pone.0216603.g004
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The organization of the actin cytoskeleton plays a central role in the regulation of YAP
localization and transcriptional activity independently of YAP phosphorylation [13]. Statins
disrupt Rho-dependent actin remodeling in at least some cell types [37] but their effect on the
actin organization of PDAC cells has not been determined. Consequently, we examined the
effect of statin exposure on actin organization in PDAC cells challenged with insulin and neu-
rotensin, as visualized by phalloidin staining. Stimulation of PDAC cells with the combination
of insulin and neurotensin induced a marked increase in the assembly of actin stress fibers, a
surrogate marker of Rho signaling. Prior exposure to cerivastatin (0.1–0.3 μM) blunted stress
fiber formation in PANC-1 (Fig 5F) and MiaPaCa-2 (Fig 5G) cells. These results imply that
statins inhibit YAP via a Hippo pathway-independent disruption of the actin cytoskeleton
organization.
In order to test further the specificity of the statins in PDAC cells, we examined whether
treatment with cerivastatin inhibts other cellular responses induced by crosstalk between insu-
lin and neurotensin. Because statins inhibited PI3K activity in other cell types [60], and this
enzyme contributes to YAP activation in PDAC cells [58], we determined the effect of cerivas-
tatin on the activity of PI3K in intact PANC-1 cells. To ascertain whether treatment with ceri-
vastatin diminishes the accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in
the plasma membrane, we monitored the redistribution of Akt-pleckstrin homology domain-
green fluorescent protein (Akt-PH-GFP) in single PANC-1 cells. In line with our previous
results, stimulation with insulin and neurotensin markedly increased membrane accumulation
of Akt-PH-GFP [58]. The translocation of the PIP3 sensor to the plasma membrane was not
prevented by prior exposure to cerivastatin at a concentration as high as 1 μM (S1 Fig). In con-
trast, the class I p110α specific inhibitor A66, tested as a positive control, abolished the move-
ment of Akt-PH-GFP to the plasma membrane (S1 Fig). In line with these results, treatment
with cerivastatin did not prevent the stimulation of p70S6K phosphorylated on Thr389, a direct
marker of mTORC1 activity, and the phosphorylation of p70S6K substrate, S6 on Ser240
induced by stimulation with neurotensin and insulin (S1 Fig). As a control, we verified that
treatment with BEZ-235, a dual PI3K/mTOR inhibitor, completely blocked the phosphoryla-
tion of these proteins, as expected [61].
Fig 5. Mechanism of action of statins in PDAC cells. A, The geranylgeranyl transferase inhibitor GGTI 298
inhibits colony formation by PDAC cells. Colony formation assays were performed as described in the Materials and
Methods section. PANC-1 or MiaPaCa-2 cells were incubated for 10 days (PANC-1 cells) or 8 days (Mia PaCa-2 cells)
with or without GGTI 298 at the indicated concentrations. The bars represent the number of colonies (mean ± SEM;
n = 4 dishes per condition). B and C, Treatment with cerivastatin does not alter YAP phosphorylation at Ser127.
PANC-1 (B) and Mia PaCa-2 (C) cells were treated for 24 h either in the absence or presence of cerivastatin (Cer,
0.3 μM) for 24h. The cultures were then stimulated with 5 nM neurotensin and 10 ng/ml insulin (NT+Ins) for 30 min as
indicated, and lysed with SDS–PAGE sample buffer. The samples were analyzed by SDS-PAGE and immunoblotting
with YAP Ser127 and YAP antibodies. Quantification of phosphorylated YAP Ser127 was performed using Multi Gauge
V3.0. from 9 independent experiments, T-test p values comparing the indicated groups to control were � p< 0.05; ��p<
.0.01. D and E, Exposure to either cerivastatin or simvastatin does not alter YAP phosphorylation at Ser127. PANC-
1 and Mia PaCa-2 cells were treated for 24 h either in the absence or presence of cerivastatin (Cer) or simvastatin (Sim)
at the indicated concentrations (in μM) for 24h. The cultures were then stimulated with 5 nM neurotensin and 10 ng/ml
insulin (NT+Ins) for 30 min as indicated, and lysed with SDS–PAGE sample buffer. The samples were analyzed by
SDS-PAGE and immunoblotting with antibodies that detect phospho YAP Ser127, YAP, phospho LATS Thr1079 and
LATS2 antibodies. Equal loading was verified by immunoblotting with actin antibody. Similar results were obtained in 4
independent experiments. F and G, Cerivastatin inhibits the assembly of actin stress fibers induced by stimulation
with insulin and neurotensin. PANC-1 (F) and Mia PaCa-2 cells (G) were treated for 24 h either in the absence or
presence of cerivastatin at the indicated concentrations for 24h prior to stimulation with 5 nM neurotensin and 10 ng/
ml insulin (NT+Ins) for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde, and stained with
TRITC-conjugated phalloidin and Hoechst 33342. Similar results were obtained in 3 independent experiments.
https://doi.org/10.1371/journal.pone.0216603.g005
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Given that an increase in the intracellular concentration of Ca2+ ([Ca2+]i) is one of the earli-
est events induced by GPCR agonists via heterotrimeric G proteins rather than monomeric
GTPases (such as Rho), we also determined the effect of statins on the increase in [Ca2+]i.
Prior exposure to cerivastatin did not prevent the increase in [Ca2+]i induced by subsequent
stimulation with neurotensin in PANC-1 cells (S1 Fig). Collectively, these results indicate that
statins inhibit YAP activation through disruption of actin organization without increasing
YAP phosphorylation at Ser127 or interfering with other signaling events in PDAC cells,
including PI3K/mTORC1 activation, and Ca2+ mobilization.
To further define the role of Rho, YAP and LATS in human PDAC, we analyzed the associ-
ation of their expression to PDAC survival in human PDAC. We used the Pathology Atlas [62]
based on the integration of publicly available data from The Cancer Genome Atlas (TCGA)
and data generated within the framework of the Human Protein Atlas (HPA) and analyzed
transcriptomics and survival in 176 PDAC patients [62]. In agreement with previous findings,
increased YAP expression is strongly associated (p<0.001) with unfavorable prognosis [17].
Similarly, expression of RhoA and RhoC mRNA levels is associated with poor survival of
PDAC (S2 Fig). In contrast, increased mRNA expression of LATS1/2, which phosphorylate
YAP at Ser127, is not associated with PDAC survival (S2 Fig). These findings support the
notion that the Rho GTPases promote YAP activity and poor PDAC survival and thus, are in
line with the conclusions drawn from the mechanistic studies presented in Fig 5.
Effect of statins on YAP localization and activity in murine KC and KPC
cells
Next, we examined the effects of cerivastatin and simvastatin on YAP localization, YAP/
TEAD-regulated gene expression and colony formation in KC cells. Treatment of KC cells
with either cerivastatin or simvastatin induced striking YAP translocation from the nucleus to
the cytoplasm, as verified by quantification of YAP nuclear/cytoplasmic (Fig 6A). Exposure to
cerivastatin or simvastatin also inhibited the expression of the YAP/TEAD-regulated genes
Ctgf, Cyr61 and Birc5 (Fig 6B). Furthermore, addition of either cerivastatin or simvastatin
strikingly inhibited colony formation by KC cells in a dose-dependent manner (Fig 6C).
A recent study concluded that statin-induced depletion of mevalonic acid destabilizes
mutant p53 protein and thereby exerts a more potent growth-inhibitory effects in cancer cells
harboring p53 mutant [63]. Although this mechanism could explain, at least partly, the statin
sensitivity of the human pancreatic cancer cells used in this study (PANC-1 and MiaPaCa-2)
which contain mutated TP53, the KC cells express wild type p53. In order to determine the
contribution of p53 mutation to statin sensitivity in murine PDAC cells, we also determined
the effects of statins on colony formation and YAP/TEAD-regulated genes in cells isolated
from the pancreas of mice expressing both KrasG12D and mutant p53 (KPC mice). We found
that cerivastatin and simvastatin inhibited colony formation and expression of Ctgf and Cyr61
in KPC cells at concentrations similar to those that produced inhibitory effects in KC cells (S3
Fig). The results indicate that the inhibitory effects of statins do not depend on the expression
of mutant p53 in murine PDAC cells.
Effect of simvastatin on initial stages of PDAC development in vivo
Recent studies demonstrated that the YAP/TAZ pathway plays a critical role in promoting the
initial stages of PDAC development, namely depletion of intact acini (acinar-ductal metapla-
sia) and formation of PanIN lesions [14, 15]. Consequently, we determined the effect of statin
on pancreatic pre-neoplastic lesions in KC mice subjected to diet-induced obesity that acceler-
ates the appearance and stage of these lesions [16]. Specifically, cohorts of KC mice were fed
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CD, HFCD, or HFCD plus simvastatin (40mg/kg orally) for 3 months. In line with our previ-
ous results [8, 9], administration of the obesogenic diet induced a marked increase in acini
depletion, inflammation and in PanIN-3 formation. Treatment with simvastatin significantly
attenuated the loss of intact acini (histological images in Fig 7A and 7B; quantification in Fig
7C), markedly reduced the pancreatitis score (calculated as in [8, 9]) and the formation of
PanIN-3 lesions (quantification in Fig 7E) induced by DIO. At the dose used, simvastatin did
not produce any adverse clinical effects, and had no effect on weight gain (Fig 7E).
Discussion
PDAC is a clinically aggressive disease that is anticipated to become the 2nd cause of cancer
fatalities during the next decade [2]. As current therapeutic approaches are limited, novel tar-
gets and agents for chemoprevention are urgently needed and will most likely arise from a
more detailed understanding of the signaling mechanisms that stimulate the promotion and
progression of pre-malignant (initiated) cells into invasive pancreatic cancer cells.
The highly conserved transcriptional co-activator YAP and its paralog TAZ, originally iden-
tified in Drosophila, are emerging as potent oncogenes for a variety of cell types [20, 64]. In
this context, a number of studies indicate that YAP and TAZ are overactive in PDAC patient
tumor samples [24, 65, 66] and associated with poor survival [17]. The YAP/TAZ pathway
assumes an added importance in PDAC because YAP is a key downstream target of Ras signal-
ing required for PanIN progression into invasive PDAC [14, 15]. Furthermore, YAP not only
Fig 6. Statins inhibit YAP nuclear localization, colony formation and the expression of Ctgf, Cyr61 and Birc5 in KC cells. A, KC cells 1 day after
plating were incubated either in absence or presence of 0.3 μM cerivastatin (Cer) or 3 μM simvastatin (Ser) for 24 h. Then, the cells were then fixed with 4%
paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. Bars represent the ratio of
nuclear/cytoplasm (50 to 75 cells). ��P 0.01 as shown by paired t-test. B, KC cells were incubated either in absence or presence of cerivastatin (Cer) or
simvastatin (Sim) at the indicated concentrations. Statins were added 1 day after plating and the incubation continued for 24 h. RNA was then isolated and
the relative levels (n = 3) of Ctgf, Cyr61 and Birc5 mRNA compared with 18s mRNA were measured by RT-qPCR. Data are presented as mean ± SEM.
Similar results were obtained in 3 independent experiments. C, KC cells were incubated for 6 days with various concentrations of cerivastatin or
simvastatin, as indicated. The bars represent the number of colonies (mean ± SEM; n = 4 cultures per condition).
https://doi.org/10.1371/journal.pone.0216603.g006
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acts downstream of K-ras but its hyper-activation can bypass the need of oncogenic K-ras in
PDAC development [7, 24] and plays a critical role in the crosstalk between GPCR agonists
and insulin [58]. In the light of these new developments, there is intense interest in targeting
YAP/TAZ in PDAC, given the urgent need of novel strategies for combating this lethal
disease.
Given the critical role of gene-regulatory programs in cancer development, inhibition of
transcription factors or their co-activators in cancer cells is a logical but challenging strategy.
Using sparse cultures of these PDAC cells, we show here that exposure to lipophilic statins
Fig 7. Simvastatin prevents the disruption in histologic pancreatic architecture induced by DIO in KC mice. A and B, Representative H&E staining
of the pancreas of a KC mouse fed the HFCD (A) or HFCD plus simvastatin (B). C, Percentage (%) of intact acini in KC mice fed the CD, HFCD or
HFCD plus simvastatin at 3 months. D, Pancreatitis score in KC mice fed CD, HFCD or HFCD plus simvastatin at 3 months. E, Percentage (%) of
PanIN-3 lesions in KC mice fed CD, HFCD or HFCD plus simvastatin at 3 months. F, Simvastatin has no effect on weight gain in KC mice fed with
either CD, HFCD, or HFCD plus simvastatin at 3 months. The number of mice used were: CD = 10; HFCD = 14; HFCD+simvastatin = 14. Values are
means ± s.d. �p< 0.05 vs. CD, #p< 0.05 vs. HFCD.
https://doi.org/10.1371/journal.pone.0216603.g007
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induces robust translocation of YAP from the nucleus to the cytoplasm. Using dense cultures
of PDAC cells, we demonstrate that statins block the translocation of YAP to the nucleus
induced by crosstalk between insulin and neurotensin signaling systems, a potent mitogenic
combination for these cells. Collectively, these results demonstrate that treatment with statins
induces YAP cytoplasmic sequestration in PDAC cells, in agreement with recent findings in
other cancer cell types [35–37].
When YAP/TAZ localize to the nucleus, they bind and activate primarily the TEA-domain
DNA-binding transcription factors (TEAD 1–4) thereby stimulating the expression of a variety
of genes [67], including CTGF and CYR61, well established YAP/TEAD-regulated genes. Here,
we found that lipophilic statins, including cerivastatin and simvastatin, markedly reduced the
mRNA levels of CTGF and CYR61 in sparse cultures of PANC-1 and MiaPaCa-2 cells and
blocked the increase in the expression of these genes induced by stimulation with neurotensin
and insulin in dense and serum-deprived cultures. Taken together, the results of YAP localiza-
tion and expression of YAP/TEAD-regulated genes indicate that statins block YAP activity by
restricting its localization to the cytoplasm. In agreement with the notion that YAP nuclear
activity stimulates the expression of genes, including CTGF and CYR61, implicated in PDAC
cell proliferation, we found that cell-permeable lipophilic statins, including cerivastatin, simva-
statin, atorvastatin and fluvastatin potently inhibit colony formation by PANC-1 and Mia-
PaCa-2 cells whereas the hydrophilic statin pravastatin did not have any detectable inhibitory
effect even at high concentrations.
We next examined the mechanism by which statins regulate YAP localization in PDAC
cells. Canonical Hippo signals are transduced through a serine/threonine kinase cascade
wherein Mst1/2 kinases, in complex with Sav1, phosphorylate and activate LATS1/2, in com-
plex with its regulatory protein MOB1/2 [12]. The activated LATS1/2 catalyzes the phosphory-
lation of YAP at five different sites, including Ser127, a residue proposed to mediate
cytoplasmic retention in its phosphorylated state, though the phosphorylation of this residue
did not impair nuclear import of YAP in a variety of cell types [13]. Previous studies resulted
in differing conclusions concerning the role of the Hippo pathway and YAP phosphorylation
in the mechanism by which statins promote YAP localization to the cytoplasm [35, 37] but
none of these studies were performed in PDAC cells. Our results demonstrate that exposure to
lipophilic statins, at concentrations that markedly inhibit YAP nuclear localization, YAP/
TEAD-regulated gene expression and colony formation, did not induce any significant change
in the phosphorylation of YAP at Ser127 or LATS at Thr1079 in PDAC cells. Accordingly, we
conclude that statins inhibit YAP activity through a Hippo pathway-independent mechanism.
A considerable body of evidence indicates that multiple signaling inputs regulate the activ-
ity of YAP through the organization of filamentous (F) actin [68, 69]. Rho plays a critical role
in F-actin organization and in the assembly of actin stress fibers in a variety of cell types [70].
Interestingly, Rho-induced actomyosin-based tension causes YAP/TAZ activation, as well as
proposed to “open” nuclear pores for YAP/TAZ nuclear import [71, 72]. Statins are specific
inhibitors of the 3-hydroxy-methylglutaryl (HMG) CoA reductase [32], the rate-limiting
enzyme in the generation of mevalonate, the first step in the biosynthesis of isoprenoids, lead-
ing to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and cholesterol.
The transfer of the geranylgeranyl moiety to a COOH-terminal cysteine of Rho GTPases is
critical for their function. Here, we produced several lines of evidence indicating that statins
inhibit YAP through a Rho-mediated mechanism: 1) exogenously added mevalonate reversed
the inhibitory effect of low concentrations of statins on nuclear localization and at least in part,
on colony formation of PDAC cells; 2) a selective inhibitor of GGTase, GGTI 298, mimicked
the inhibitory effect of statins on colony formation by PDAC cells; 3) treatment of PDAC cells
with cerivastatin drastically reduced stress fiber formation. These results, together with the
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dissociation from YAP phosphorylation discussed above, imply that statins inhibit YAP activ-
ity by interfering with the polymerization of the actin cytoskeleton. In line with these mecha-
nistic studies, we found that the increased expression of Rho GTPases (RhoA, RhoC) is
associated with poor survival in PDAC patients.
We extended these findings to murine PDAC and to a mouse model of acinar-ductal meta-
plasia, PanIN formation and PDAC development. Initially, we demonstrated that treatment of
cells isolated from the pancreas of KC or KPC mice with lipophilic statins induced striking
YAP translocation from the nucleus to the cytoplasm, inhibited the expression of the YAP/
TEAD-regulated genes Ctgf, Cyr61 and Birc5 and profoundly inhibited colony formation by
these cells. The results with murine cells are in agreement with the findings in human PDAC
cells and additionally imply that mutation of p53 is not necessary for high statin sensitivity, at
least in murine cells.
Subsequently, we determined the impact of a lipophilic statin on early neoplastic changes in
the pancreas of KC mice subjected to DIO, a condition that markedly accelerates the develop-
ment of pancreatic neoplastic lesions. We found that treatment with simvastatin significantly
reversed the loss of intact acini induced by DIO and markedly reduced the formation of
PanIN-3 lesions. Collectively, our results provide robust preclinical evidence that statin admin-
istration provides a plausible strategy to be considered in the prevention and treatment of
PDAC.
In line with this conclusion, recent epidemiological studies imply that the use of statins is
associated with beneficial effects in PDAC [38–47], and other malignancies [48]. Although a
recent study failed to detect an effect of statins in lowering PDAC risk [73], a follow up study
of the same data reported an increased survival in PDAC patients with regular pre-diagnosis
use of statins [74]. Taken together with the findings presented here and the lack of efficient
strategies to oppose PDAC development, these studies warrant a comprehensive evaluation of
the lipophilic statins in the primary or secondary chemoprevention of this devastating disease.
Supporting information
S1 Fig. Treatment with cerivastatin does not prevent PI3K activation or increase in [Ca2+]i
in PANC-1 cells. A: PANC-1 cells were transiently transfected with a plasmid encoding a
fusion protein between GFP and the PH domain of AKT (AKT-PH-GFP). After 24h, the cul-
tures were incubated in DMEM without or with cerivastatin at the indicated concentrations
for 18h prior to stimulation with 5 nM neurotensin and 10 ng/ml insulin. Other cultures were-
treated with the class I p110α specific inhibitor A66 at 10 μM, tested as a positive control The
intracellular distribution of AKT-PH-GFP was monitored under a fluorescence microscope.
The selected cells displayed in the figures were representative of 90% of the population of
GFP-positive cells. B: PANC-1 cells were treated for 24 h either in the absence or presence of
cerivastatin (Cer) at the indicated concentrations for 24h. Other cultures were incubated for
2h with the either the MEK inhibitor PD0325901 (1μM, PD) or the dual PI3K/mTOR inhibitor
NPV-BEZ235 (1μM, BEZ). All cultures were then stimulated with 5 nM neurotensin and 10
ng/ml insulin (NT+Ins) for 30 min as indicated, and lysed with SDS–PAGE sample buffer.
The samples were analyzed by SDS-PAGE and immunoblotting with phospho-p70 S6 Kina-
seThr-389 and phospho-S6 Ribosomal Protein Ser-240/244. Equal loading was verified by
immunoblotting with GAPDH antibody.Similar results were obtained in 2 independent exper-
iments. C: PANC-1 cells were incubated without or with cerivastatin at the indicated concen-
trations for 18h prior to stimulation with 5 nM neurotensin. Intracellular [Ca2+]i was
monitored as described in Materials and Methods.
(TIF)
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S2 Fig. Kaplan-Meier plots for RHO and LATS expression in PDAC. Images were repro-
duced from the Human Protein Atlas (version 17) available from www.proteinatlas.org The
link is: http://www.proteinatlas.org/ENSG00000137693YAP1/pathology/tissue/pancreatic
+cancerS1
(TIF)
S3 Fig. Statins inhibit colony formation and the expression of CTGF, CYR61 and BIRC5 in
KPC cells. A, KPC cells were incubated for 6 days with various concentrations of cerivastatin
or simvastatin, as indicated. The bars represent the number of colonies (mean ± SEM; n = 4
dishes per condition). B, KPC cells were incubated either in absence or presence of cerivastatin
(Cer) or simvastatin (Sim) at the indicated concentrations. Statins were added 1 day after plat-
ing and the incubation continued for 24 h. RNA was then isolated and the relative levels
(n = 3) of CTGF, CYR61 and BIRC5 mRNA compared with 18s mRNA were measured by RT-
qPCR. Data are presented as mean ± SEM. Similar results were obtained in 3 independent
experiments.
(TIF)
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